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Background: Abnormal NK phenotype and cytotoxic functions have been described in acute myeloid leukemia,
chronic lymphocytic leukemia, myeloma and myelodysplastic syndromes. Defective NK cytotoxicity is due to
decreased expression of the Natural Cytotoxicity Receptors (NCRs), 2B4/CD244/p38, or NKG2D. This prompted us to
test the expression of these molecules on circulating NK cells from patients with AIDS-related lymphomas (RL) in
comparison with HIV + patients without lymphoma, healthy subjects and HIV-negative patients with lymphoma.
Methods: Blood samples were analyzed by flow cytometry for NCRs, 2B4/CD244/p38 and NKG2D expression on NK
cells defined as CD3-/CD56+ lymphocytes. We also analyzed by quantitative PCR specific RNA for NKp30/NCR3 and
NKp46/NCR1.
Results: We could not detect any defect in NKp46/NCR1 expression between all groups. NKp44/NCR2, NKp30/NCR3
and NKG2D had lower expression in AIDS-RL in comparison with HIV + patients without lymphoma when compared
to patients with similar (>0.3 G/L) CD4+ lymphocyte levels. Expression of 2B4/CD244/p38 was lower in AIDS-RL than
in HIV-negative lymphoma. Comparison of specific NKp30/NCR3 and NKp46/NCR1 RNA showed increased steady
state levels, despite decreased surface expression for NKp30/NCR3, suggesting abnormal post-transcriptional
regulatory mechanisms.
Conclusions: We show a more pronounced defect in NK activating molecule when HIV infection is associated with
lymphoma than when only one condition (HIV positivity or lymphoma) is present. Defective NK phenotype, in
addition to CD4+ depletion and dysfunction, may participate to the increased incidence of lymphoma in HIV
patients.
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Advances in lymphoma treatment prolong progression-
free survival. Nonetheless, many patients relapse. Defi-
cient cytotoxic functions of natural killer (NK) cells [1],
which can be infected by HIV [2], may participate in the
failure to cure AIDS-related lymphomas (AIDS-RL). En-
gagement of inhibitory receptors by human leukocyte
antigen (HLA)-class-I molecules inhibits NK cytotox-
icity. Thus, according to the “missing self hypothesis”,
absent or deficient expression of HLA-class-I molecule* Correspondence: regis.costello@free.fr
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article, unless otherwise stated.activates NK if an additional activating signal is delivered
by the natural cytotoxicity receptors (NCR) NKp30/
NCR3, NKp44/NCR2 or NKp46/NCR1, 2B4/CD244/p38
and NKG2D. Deficient NK functions interfere with the
anti-tumor response: 1) during treatment, via decreased
efficiency of anti-CD20 antibody-driven cell cytotoxicity
(ADCC) [3-5] 2) during the complete remission phase
by favoring residual HLA-class-I negative lymphoma
cells to escape from NK-mediated immunity [6]. Abnor-
mal NK functions have been described in hematological
malignancies such as acute myeloid leukemia, chronic
lymphocytic leukemia, myeloma and myelodysplastic
syndromes [7-10]. Of note, down-regulation of NCRs is
associated with HIV infection [11]. We compared the
NK cell surface activating molecules expression betweenCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Among the 31 AIDS-RL (mean age: 43 ± 8 years) of the
study, 20 had CD4+ lymphocytes <300/mm3 (mean
133 ± 70/mm3), 11 had CD4+ lymphocytes >300/mm3
(mean 630 ± 260/mm3). Only 2 patients (6.4%) were not
treated by highly active antiretroviral therapy (HAART)
at study inclusion. The control cohort included 56
HIV-positive patients without lymphoma (mean age:
44 ± 9 years) selected to be matched for the CD4+
lymphocyte count with the AIDS-RL: among this popu-
lation, 9 patients [16%] were not treated by HAART.
Two groups were designed: HIV patients with <300
CD4+ lymphocytes/mm3 (n = 12; mean age 44 ± 8.4 years,
1 patient without HAART) and HIV patients with >300
CD4+ lymphocytes/mm3 (n = 44; mean age 44 ± 9.8 years
patients without HAART). Two other control cohorts of 33
HIV-negative lymphoma patients (mean age: 62 ± 14 years)
and 19 healthy subjects (HS, mean age: 41 ± 16 years)
were included.
Lymphoid cells repartition (Figure 1– Panel A)
There was no significant difference in total lymphocytes
and T-lymphocytes count among the different groups
(p > 0.05). Lymphoma groups had more B lymphocytes
(1700 ± 7000/mm3) than HIV (200 ± 200/mm3) and HS
(300 ± 100/mm3) because of lymphoma circulating cells.
Total NK cells counts in AIDS-RL with <300 CD4+ lym-
phocytes/mm3 and HIV + patients without lymphoma but
with <300 CD4+ lymphocytes/mm3 were lower than in
the other groups (mean 41 ± 35/mm3 for AIDS-RL <300
CD4+ lymphocytes/mm3 and 51 ± 52/mm3 for HIV +
without lymphoma with <300 CD4+ lymphocytes/mm3
vs 137 ± 257/mm3 for AIDS-RL with >300 CD4+ lympho-
cytes/mm3, 131 ± 148/mm3 for HIV + with >300 CD4+
lymphocytes/mm3, 276 ± 510/mm3 for HIV-negative
lymphoma patients and 150 ± 70/mm3 for HS (p = 0.04
and 0.02).
NK activating receptors expression (Figure 1-Panel B,
C, D, E, F)
No difference in NKp46/NCR1 expression was observed
(Figure 1, panel B, p > 0.05, NS). The analysis of NKp44/
NCR2 expression, an activating receptor only expressed
on activated NKs (Figure 1, panel C) showed no differ-
ence between AIDS-RL and HIV-negative lymphoma pa-
tients (p > 0.05, NS) and between AIDS-RL and HIVpatients without lymphoma but with <300 CD4/mm3
patients (p > 0.05, NS). However, AIDS-RL with >300
CD4+ lymphocytes/mm3 expressed lower NKp44/NCR2
than HIV + patients without lymphoma with >300 CD4+
lymphocytes/mm3 (MFIr median (M) = 1.52; interquartile
range (IQR)[1.24-1.850] vs M = 1.80 IQR[1.540-2.110],
p = 0.011) and than HS (M = 1.75 IQR[1.650-2.000],
p = 0.006). In spite of a very high NKp44/NCR2 expres-
sion by one HIV + lymphoma with <300 CD4+ lympho-
cytes/mm3 (MFIr =6.21), this group tended to express
lower NKp44/NCR2 than HIV + patients with >300
CD4+ lymphocytes/mm3 (M = 1.42 IQR[1.320-1.765] vs
1.80[1.543-2.115], p = 0.06). HIV-negative lymphoma
patients expressed more NKp44/NCR2 than HIV + pa-
tients without lymphoma and >300 CD4+ lymphocytes/
mm3 (M = 1.48 IQR[1.330-1.690] vs 1.80[1.543-2.115],
p = 0.02) or HS (M = 1.75[1.650-2.000], p = 0.002). There
was no difference in NKp30/NCR3 expression (Figure 1,
panel D) between AIDS-RL and HIV-negative lymph-
oma patients (p > 0.05, NS) or between AIDS-RL and
HIV + patients without lymphoma and <300 CD4+ lym-
phocytes/mm3 (p > 0.05, NS). NKp30/NCR3 expression
was lower in AIDS-RL with >300 CD4+ lymphocytes/mm3
than in HIV + patients without lymphoma and >300 CD4+
lymphocytes/mm3 (M= 4.555 IQR[2.693-9.645] vs 7.525
[4.853-16.19], p = 0.014) or HS (M= 8.86 IQR[4.630-14.56],
p = 0.041).
Regarding NKG2D (Figure 1, panel E), AIDS-RL patients
with <300 CD4+ lymphocytes/mm3 had a lower expres-
sion of NKG2D than AIDS-RL patients with >300 CD4+
lymphocytes/mm3 (M = 15.92 IQR[8.125-29.93] vs 29.18
[18.18-41.32], p = 0.036), than HIV + patients without
lymphoma but >300 CD4+ lymphocytes/mm3 (M= 24.92
IQR[18.68-35.45], p = 0.005), than HIV-negative lymph-
oma patients (M = 31.89 IQR[25.71-42.17], p = 0.001),
or than HS (M = 31.78 IQR[27.40-37.50], p = 0.001).
AIDS-RL with >300 CD4+ lymphocytes/mm3 had lower
expression of NKG2D than HIV-negative lymphoma
patients (M = 23.65 IQR[15.45-28.19] vs 31.89[25.71-
42.17], p = 0.03), than HS (M = 31.78 IQR[27.40-37.50],
p = 0.005) or HIV + patients without lymphoma but >300
CD4+ lymphocytes/mm3 (M = 24.92 IQR[18.68-35.45],
p = 0.005).
We failed to detect 2B4/CD244/P38 expression difference
(Figure 1, panel F) between AIDS-RL and HIV + patients
without lymphoma (NS, p > 0.05). 2B4/CD244/P38 expres-
sion was lower in AIDS-RL with <300 CD4+ lymphocytes/
mm3 than in HIV-negative lymphoma patients (M= 37.36
IQR[21.45-51.68] vs 63.43[45.16-86.86], p = 0.002) and than
in HS (M= 51.64[38.93-78.76], p = 0.023). 2B4/CD244/P38
expression was lower in AIDS-RL with >300 CD4+
lymphocytes/mm3 than in HIV-negative lymphoma pa-
tients (M = 41.11 IQR[32.18-50.35] vs 63.43[45.16-86.86],
p = 0.012).
Figure 1 (See legend on next page.)
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Figure 1 Flow cytometry analysis of whole PBMC population (panel A) and of NK cells (panels B to F). Results are expressed as absolute
numbers of cells per volume unit, i.e. Giga/Liter in panel A. Results are expressed as mean fluorescence intensity ratio (in comparison with isotype
controls, cf. Material and Methods). When significant, statistical results are indicated with the corresponding p-value. The number of analyzed
patients was: AIDS-RL/CD4 < 300/mm3 = 20, AIDS-RL/CD4 > 300/mm3 = 11, HIV + <300 CD4/mm3 = 12, HIV+ > 400 CD4/mm3 = 44, non AIDS-RL
lymphoma = 33, control HS = 19.
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In line with cell surface expression, AIDS-RL had
no modification of NKp46/NCR1 specific RNA level
(0.5 < normalized ratio <2 for the 6 of the 7 patients ana-
lyzed) compared with HIV + population without lymph-
oma (Panel A). We did not find any correlation between
NKp46/NCR1 expression and CD4+ lymphocyte count.
On the contrary, NKp30/NCR3 RNA (Panel B) was over-
expressed in AIDS-RL patients (normalized ratio >2 for
the 7 patients analyzed). No significant RNA level was
detected for NKp44/NCR2, a results in line with normal
physiology since this molecule is only expressed by
stimulated NKs (data not shown).Figure 2 RT-qPCR analysis of NKp46/NCR1 (panel A) and
NKp30/NCR3 (panel B). Values fewer than 2 correspond to an RNA
expression not statistically superior to the gene control, value above
2 correspond to over-expressed RNA. Data correspond the RNA
levels ratios between 7 AIDS-RL samples versus 32 HIV-positive
patients without lymphoma.Discussion
The total NK cells count in patients with <300 CD4+
lymphocytes/mm3 was lower in AIDS-RL in comparison
with the other groups, suggesting a poor prognosis as
shown in low or high grade HIV-negative lymphomas
[12,13]. Low circulating counts concerned the NK
CD56bright and CD56low subsets, while the ineffective
CD56negative subpopulation was elevated in AIDS-RL
(data not shown). Regarding the NCR we found no
difference in NKp46/NCR1 expression in the different
groups but, in contrast, a significant decrease in both
NKp44/NCR2 and NKp30/NCR3 was observed in
AIDS-RL with >300 CD4/mm3 in comparison with
HIV + patients with comparable CD4+ lymphocytes. Thus
in moderately immune-suppressed patients the develop-
ment of lymphoma is associated with low expression of
two activating molecules. Regarding NKp44/NCR2, low
levels should be of good prognosis since NK cells in
HIV-controller patients do not up-regulate NKp44/
NCR2 thus protecting uninfected CD4+ lymphocytes
from inadequate NK killing [14]. Regarding the mechan-
ism of NCR regulation, quantitative RT-PCR measured
comparable NKp46/NCR1 levels in AIDS-RL and con-
trols, suggesting an identical regulation at both transcrip-
tional and post-transcriptional levels. However elevated
level of NKp30/NCR3 specific RNA was detected in
AIDS-RL in comparison with HIV patients without
lymphoma, despite identical surface expression of NKp30/
NCR3. This suggests that a post-transcriptional mechan-
ism negatively interferes with NKp30/NCR3 RNA traduc-
tion or protein stability, leading to identical surface
expression despite higher specific RNA levels. Regarding
NKG2D, we observed a gradient of expression from lower
level (AIDS-RL <300 CD4/mm3) to HS/HIV-negative
lymphoma patients, with intermediary levels for AIDS-RL
with >0.3 G/L CD4+ lymphocytes followed by HIV + pa-
tients without lymphoma. The NKG2D ligands MICA/
MICB/ULBP are stress molecules expressed on tumor
cells, and secreted at high levels in HIV patients, leading
to down-regulated NKG2D expression on NK and im-
paired anti-lymphoma cytotoxicity [15]. Expression of
2B4/CD244/p38 was lower in AIDS-RL than in HIV-
negative lymphoma patients. The 2B4/CD244/p38 lig-
and is the CD48 molecule [16,17] which is expressed
on B normal and neoplastic lymphocyte and is drastically
up-regulated by Ebstein-Barr virus (EBV) infection. The
Mercier-Bataille et al. AIDS Research and Therapy 2014, 11:38 Page 5 of 6
http://www.aidsrestherapy.com/content/11/1/38down-regulation of 2B4/CD244/p38 could thus impair the
cytotoxicity against EBV-positive B-cell lymphomas.Conclusion
The AIDS-RL patients had decreased levels of 2 out of 3
NCRs, of NKG2D and of 2B4/CD244/p38. The most sig-
nificant difference concerned NKG2D, which expression
was significantly decreased regarding both HIV patients
without lymphoma, non-HIV lymphoma patients and
HS. This specific abnormality is of great interest since
lymphoma cells express the stress ligands MICA/B and
ULBP, but may escape to NK cytotoxicity due to im-
paired NKG2D expression. Of note, HAART was not
sufficient to restore a normal phenotype since most of
our patients were already treated at the time of NK
phenotype analysis, with NK abnormalities also detected
in patient with CD4+ lymphocytes >300/mm3. Since
defects in NK immune surveillance may also impair
the anti-infectious immunity, they could also partly
explain the susceptibility to infection of HIV patients
during chemotherapy, even in patients with high
CD4+ T-lymphocytes levels. Altogether our data sug-
gest than immune intervention aiming at NK cell func-
tion restoration could be of interest in AIDS-RL
patients.Material and methods
Study design
According to previous data [8], we hypothesized that
75% ±10% of AIDS-RL patients and 15% ±10% of HIV
patients without lymphoma had low NCR expression
(NCRdull). In order to show a statistically significant differ-
ence between the 2 groups with a risk α = 5% and β = 75%,
we included in our study 31 AIDS-RL patients and 56 HIV
positive patients without lymphoma.Patients
From July 2006 to June 2011 patients from Marseille,
Nice and Paris were included in first line of therapy. In-
clusion criteria were the co-existence of HIV infection
with biopsy-proven lymphoma. The 56 HIV positive pa-
tients without lymphoma were recruited from Service
des Maladies Infectieuses (Hôpital Nord, Marseille). Ac-
cording to Helsinki declaration, patients were informed
and signed a consent form. Biological samples were col-
lected at diagnosis time, before lymphoma treatment.
Additional comparison of our data was also performed
with 33 non-HIV patients with lymphoma and 19 healthy
subjects (HS).
This study was approved by the Comité de Protection
des Personnes (CPP) Aix-Marseille II.Blood samples and cell separation
Blood samples were collected on EDTA and analyzed
by flow cytometry. Dry pellets of PBMC were frozen
at −80°C for subsequent quantitative RT-PCR analysis.
qRT-PCR analysis
qRT-PCR analysis concerned 7 AIDS-RL patients and 32
HIV-positive patients without lymphoma. qRT-PCR analysis
was performed with the Applied Biosystems 7900HT Fast
Real-Time PCR system using Taqman detection. Total
RNA was isolated using TRIzol reagent (Invitrogen Life
Technologies). Capture of fluorescence was recorded on
the ABI Prism 7900HT scanner and the Ct (threshold
cycle) was calculated for each assay (Sequence Detection
System Software 2.3, Applied Biosystems). We used
GAPDH as endogenous control (ΔCt = Ct target gene −
Ct GAPDH). GAPDH TaqMan Gene Expression assays
were from Applied Biosystems. Since the NCR expression
is almost exclusively restricted to NK, the PCR was per-
formed on the whole PBMC population, but the values
were adjusted to the percentage of NK present in each
sample. We compared ΔCt with the mean of VIH ΔCt
using a ratio (ΔCt HIV + Lymphoma/ΔCt HIV), consider-
ing that a ratio >2 corresponded to RNA overexpression.
Phenotypic analysis
Flow cytometry was performed on an Epics XLR flow
cytometer (Beckman Coulter). The NK cells were defined
as CD3-/CD56+/CD16+. The following mAbs were
used (Beckman-Coulter, Marseille, France): anti-CD3FITC
(UCHT1), anti-CD56PC5 (N901-NKH1), anti-NCR1/
NKp46PE (BAB281), anti-NCR2/NKp44PE (Z231), anti-
NCR3/NKp30PE (Z25), anti-NKG2D-PE (ON72), anti-P38
(C1.7), anti-IgG1-FITC, anti-CD19-PC5 (J4.119), CD4-PE/
CD8-ECD/CD3-PC5, anti-CD3-FITC/CD16-PE (UCHT1/3G8).
All our results were expressed as the mean fluorescent in-
tensity ratio molecule of interest/isotypic control (MFIr).
Statistical analysis
Data were compared between the 4 groups using a non-
parametric Kruskal-Wallis test; post hoc tests for multiple
comparisons were performed when the test was significant
(macro Marta Garcia-Granero [07/2008] for SPSS). The
statistical analyses were performed using the SPSS soft-
ware package, version 17.0 (SPSS Inc., Chicago, IL, USA).
All tests were two-sided. Statistical significance was de-
fined as p <0.05.
Abbreviations
NK: Natural killer; NCR: Natural cytotoxicity receptors; AIDS-RL: AIDS-related
lymphoma; HS: Healthy sublects; MFI: Mean fluorescent intensity;
PBMC: Peripheral blood mononucleated cells; PCR: Polymerase chain
reaction.
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